United States Cell-Free DNA Market Insight
Published: 19 June 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United States Cell-Free DNA Market is projected to grow at a CAGR of around 13.8%, driven by increasing adoption of liquid biopsy technologies, expanding utilization of non-invasive prenatal testing, rising cancer prevalence, and growing emphasis on precision medicine across healthcare systems.
United States Cell-Free DNA Market Forecasts to 2035
- The United States Cell-Free DNA Market Size Was Estimated at USD 2.4 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 13.8% from 2025 to 2035.
- The United States Cell-Free DNA Market Size is Expected to Reach around USD 8.8 Billion by 2035.
Notable Insights for the United States Cell-Free DNA Market
- Segmentation Based on Application, Non-Invasive Prenatal Testing (NIPT) held the dominant position in 2025 with nearly 43.7% share, supported by growing maternal age, expanding reimbursement coverage, and increasing physician preference for early genetic screening.
- Segmentation Based on Sample Type, Blood Plasma accounted for approximately 71.4% share in 2025, owing to its high diagnostic reliability, ease of collection, and extensive use across oncology and prenatal testing applications.
- The market is led by Natera, Inc.; the company generated approximately USD 1.71 billion in revenue during FY2025, supported by strong adoption of its Signatera and Panorama testing portfolio across the United States.
- Guardant Health, Inc. reported nearly USD 890 million revenue in FY2025, while Illumina, Inc. generated approximately USD 4.46 billion, reflecting the strong commercial presence of established genomic diagnostics companies.
Download the eBook (ToC)
Research Methodologies Used to Analyze the United States Cell-Free DNA Market
This study employs a combination of primary and secondary research methodologies to analyze the United States Cell-Free DNA Market. Primary research includes interviews and discussions with molecular diagnostic companies, oncologists, obstetricians, clinical laboratory professionals, genomic researchers, healthcare providers, reimbursement specialists, and industry experts. Secondary research involves company annual reports, investor presentations, CDC databases, NIH publications, peer-reviewed journals, industry associations, regulatory filings, and commercial research sources. Market estimations are developed through top-down and bottom-up approaches, while data validation and triangulation techniques ensure reliable market sizing, forecasting, and competitive assessment.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States cell-free dna market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Cell-Free DNA Market
• Natera, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings (Labcorp)
• Quest Diagnostics Incorporated
• Exact Sciences Corporation
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Myriad Genetics, Inc.
Recent Developments:
- In October 2025, Natera, Inc. launched an enhanced version of its Signatera molecular residual disease assay featuring broader genomic profiling capabilities to improve cancer recurrence monitoring and personalized treatment decision-making.
- In July 2025, Guardant Health collaborated with a leading U.S. oncology network to expand access to comprehensive liquid biopsy testing and accelerate the adoption of precision oncology programs across community care settings.
Market Segmentation:
United States Cell-Free DNA Market, By Application
• Non-Invasive Prenatal Testing (NIPT)
• Oncology and Liquid Biopsy
• Transplant Rejection Monitoring
• Early Disease Detection
• Research Applications
• Others
United States Cell-Free DNA Market, By Sample Type
• Blood Plasma
• Serum
• Urine
• Cerebrospinal Fluid
• Others
United States Cell-Free DNA Market, By Technology
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray Technologies
• Digital PCR
• Others
United States Cell-Free DNA Market, By End User
• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutes
• Specialty Clinics
• Biopharmaceutical Companies
United States Cell-Free DNA Market, By Indication
• Prenatal Disorders
• Cancer
• Organ Transplantation
• Genetic Disorders
• Others
Expert Views:
The United States Cell-Free DNA Market is anticipated to witness robust growth through 2035, fueled by the expanding clinical utility of liquid biopsy technologies, rising acceptance of non-invasive diagnostic approaches, and continuous innovation in genomic testing. Increasing investments in precision medicine and broader integration of cell-free DNA testing into routine clinical workflows are expected to create substantial opportunities for market participants over the forecast period.
Author: Govind and Krishna By Decisions Advisors and Consulting